Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 823-834

  Kalantar Zadeh, Kamyar ^a,b   Lee, Grace H ^a   Miller, Jessica E ^a,b   Streja, Elani ^a,b   Jing, Jennie ^a   Robertson, John A ^c   Kovesdy, Csaba P ^d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DAVITA INC   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease (CKD); confounding by medical indication (CMI); Erythropoiesis stimulating agent (ESA); ESA hyporesponsiveness; hemoglobin variability; high turnover bone disease; iron markers; repeated measure model

Indexed keywords

ALKALINE PHOSPHATASE; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN DIET; RENAL OSTEODYSTROPHY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 60149091852     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.12.040     Document Type: Article

References (64)

1. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
2. Levin A. The treatment of anemia in chronic kidney disease: Understandings in 2006. Curr Opin Nephrol Hypertens 16 (2007) 267-271
3. Brimble K.S., and Clase C.M. Hemoglobin variability in dialysis patients. J Am Soc Nephrol 18 (2007) 2218-2220
4. Berns J.S., and Fishbane S. Hemoglobin variability: Random fluctuation, epiphenomenon, or phenomenon?. Semin Dial 19 (2006) 257-259
5. Cotter D., Zhang Y., Thamer M., Kaufman J., and Hernan M.A. The effect of epoetin dose on hematocrit. Kidney Int 73 (2008) 347-353
6. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736
7. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
8. Kalantar-Zadeh K., and Aronoff G.R. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 20 (2009) 479-487
9. Yang W., Israni R.K., Brunelli S.M., Joffe M.M., Fishbane S., and Feldman H.I. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18 (2007) 3164-3170
10. Gilbertson D.T., Ebben J.P., Foley R.N., Weinhandl E.D., Bradbury B.D., and Collins A.J. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3 (2008) 133-138
11. Kilpatrick R.D., Critchlow C.W., Fishbane S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1077-1083
12. Berns J.S., Elzein H., Lynn R.I., Fishbane S., Meisels I.S., and Deoreo P.B. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64 (2003) 1514-1521
13. Gunnell J., Yeun J.Y., Depner T.A., and Kaysen G.A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
14. Kalantar-Zadeh K., Hoffken B., Wunsch H., Fink H., Kleiner M., and Luft F.C. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995) 292-299
15. Rao D.S., Shih M.S., and Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 (1993) 171-175
16. Van Wyck D.B., Bailie G., and Aronoff G. Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 39 (2002) 426-432
17. Horl W.H. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18 (2007) 382-393
18. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of hemoglobin target. Am J Kidney Dis 50 (2007) 471-530
19. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S146
20. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 suppl 1 (2003) S1-S202
21. Regidor D.L., Kovesdy C.P., Mehrotra R., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19 (2008) 2193-2203
22. Blayney M.J., Pisoni R.L., Bragg-Gresham J.L., et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74 (2008) 655-663
23. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-780
24. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
25. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
26. Kalantar-Zadeh K., Kilpatrick R.D., Kuwae N., et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 20 (2005) 1880-1888
27. Shinaberger C.S., Kilpatrick R.D., Regidor D.L., et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 48 (2006) 37-49
28. Kilpatrick R.D., McAllister C.J., Kovesdy C.P., Derose S.F., Kopple J.D., and Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18 (2007) 293-303
29. Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J., et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18 (2007) 1584-1593
30. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 30 (2007) 1049-1055
31. Kovesdy C.P., Regidor D.L., Mehrotra R., et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2 (2007) 999-1007
32. Longenecker J.C., Coresh J., Klag M.J., et al. Validation of comorbid conditions on the End-Stage Renal Disease Medical Evidence Report: The CHOICE Study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11 (2000) 520-529
33. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., and Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321 (1989) 158-163
34. Shinaberger C.S., Kopple J.D., Kovesdy C.P., et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1769-1776
35. Diggle P., Heagerty P., Liang K.Y., and Zeger S.L. Analysis of Longitudinal Data (2002), Oxford University, Oxford, UK
36. Coyne D.W. Use of epoetin in chronic renal failure. JAMA 297 (2007) 1713-1716
37. Steinbrook R. Medicare and erythropoietin. N Engl J Med 356 (2007) 4-6
38. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernan M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
39. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Am J Kidney Dis 49 (2007) 1-296
40. Cotter D.J., Stefanik K., Zhang Y., and Thamer M. Improved survival with higher hematocrits: Where is the evidence?. Semin Dial 17 (2004) 181-183
41. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
42. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
43. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
44. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
45. Ebben J.P., Gilbertson D.T., Foley R.N., and Collins A.J. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 (2006) 1205-1210
46. Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 (2008) 391-398
47. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Lee G.H., Nissenson A.R., and Kopple J.D. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
48. Kalantar-Zadeh K., Block G., McAllister C.J., Humphreys M.H., and Kopple J.D. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 80 (2004) 299-307
49. Stenvinkel P., and Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; Links to inflammation and oxidative stress. Nephrol Dial Transplant 17 suppl 5 (2002) S32-S37
50. Fishbane S. Upper limit of serum ferritin: Misinterpretation of the 2006 KDOQI Anemia Guidelines. Semin Dial 21 (2008) 217-220
51. Fishbane S., Kalantar-Zadeh K., and Nissenson A.R. Serum ferritin in chronic kidney disease: Reconsidering the upper limit for iron treatment. Semin Dial 17 (2004) 336-341
52. Kalantar-Zadeh K., Streja E., Miller J.E., and Nissenson A.R. Intravenous iron vs. erythropoiesis stimulating agents: Friends or foes in treating CKD aAnemia?. Adv Chronic Kidney Dis (2009) (in press)
53. Canavese C., Bergamo D., Ciccone G., et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65 (2004) 1091-1098
54. Smith R.J., Davis P., Thomson A.B., Wadsworth L.D., and Fackre P. Serum ferritin levels in anemia of rheumatoid arthritis. J Rheumatol 4 (1977) 389-392
55. Kalantar-Zadeh K., Kalantar-Zadeh K., and Lee G.H. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Neph 1 suppl 1 (2006) S9-S18
56. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
57. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
58. Brancaccio D., Cozzolino M., and Gallieni M. Hyperparathyroidism and anemia in uremic subjects: A combined therapeutic approach. J Am Soc Nephrol 15 suppl 1 (2004) S21-S24
59. Papayannopoulou T., D'Andrea A.D., Abkowitz J.L., and Migliaccio A.R. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R., Benz E.J., and Shattil S.J. (Eds). Hematology Basic Principles and Practice. ed 4 (2005), Elsevier Churchill Livingstone, Philadelphia, PA 267-288
60. Gallieni M., Corsi C., and Brancaccio D. Hyperparathyroidism and anemia in renal failure. Am J Nephrol 20 (2000) 89-96
61. Goicoechea M., Vazquez M.I., Ruiz M.A., Gomez-Campdera F., Perez-Garcia R., and Valderrabano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 78 (1998) 23-27
62. Courtney A.E., McNamee P.T., and Maxwell A.P. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients. Nephron Clin Pract 107 (2007) c14-c19
63. Churchill D.N., Macarios D., Attard C., Kallich J., and Goeree R. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract 106 (2007) c193-c198
64. Pizzi L.T., Patel N.M., Maio V.M., et al. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transplant 35 (2006) 660-671